MUCKRAKING CORNER- TTNP
Spec Buy
Activist Investing nominates slate of director candidates for Titan board 08:11 TTNP David Lazar, CEO of Activist Investing, one of the largest stockholders of Titan Pharmaceuticals, Inc. with 25.2% of the Company's outstanding shares, issued the following statement: "We have submitted a request for the Company to hold a special meeting of the Company's stockholders to expand the size of Titan's Board of Directors by six directors and to elect our slate of six highly qualified professionals, Avraham Ben-Tzvi, Peter Chasey, Eric Greenberg, David Lazar, Matthew McMurdo and David Natan, to fill the resulting Board vacancies in order to progress the Company's previously announced review of strategic alternatives. The Nominees collectively possess decades of experience in strategic turnarounds, deal structuring, corporate governance, investment management, accounting, finance and corporate law, which we believe will be extremely additive to the Company and its ability to unlock significant stockholder value through a strategic transaction. As disclosed by the Company, the Special Meeting will be held on August 2, 2022 with a corresponding record date of July 22, 2022 to determine the stockholders entitled to vote on our proposals at the Special Meeting. We look forward to communicating further with fellow stockholders in the coming weeks and will be filing proxy materials to solicit votes to materially reconstitute the Board at the Special Meeting with our Nominees."
Show Related Items >> Last Tuesday Titan announces FDA clearance of IND application for Nalmefene Implant 08:02 TTNP Titan Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug, IND, application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder, OUD. Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan, commented, "FDA clearance of the IND for our ProNeura-based nalmefene implant marks an important milestone in developing a novel product that may help answer the call for long-term treatment options in addiction medicine. We are very grateful for the support we received from the National Institute for Drug Addiction, or NIDA, that enabled us to meet this objective."
